Written question asked by Andrew Hunter (Democratic Unionist Party) on Monday, 10 January 2005, in the House of Commons. It was due for an answer on Monday, 24 January 2005. It was answered by Baroness Winterton of Doncaster (Labour) on Monday, 24 January 2005 on behalf of the Department of Health.
Dept of Health
- Question
- To ask the Secretary of State for Health, if he will take measures to reduce the time between the Medicines and Healthcare Products Regulatory Agency granting a licence to first-in-class medicines and the issuing of guidance by the National Institute for Clinical Excellence; and if he will make a statement; if he will instruct primary care trusts to give equal consideration to the routine use of medicines which are not reviewed by the National Institute for Clinical Excellence (NICE) and those which are to be reviewed by NICE; and if he will make a statement; if he will direct the National Institute for Clinical Excellence to issue general guidance for new medicines at the time of their launch, followed by a full review or clinical guidance; and if he will make a statement. - Inc ref to Health Service Circular 1999/176.
Secondary information
- Type
- Written question
- Reference
- 430 c173W; 208181;208182;208183
- Session
- 2004-05
- Subjects
- Licensing Drugs Prescription drugs Prescriptions National Institute for Clinical Excellence
- Link
- View this Written question on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2013-11-24 23:28:17 +0000
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_985099
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_985099
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_985099